Back to Search
Start Over
Duration of Bare Sclera Pterygium Surgery Combined with Mitomycin C with and Without Tranexamic Acid: A Randomized Double-Blind Controlled Trial.
- Source :
-
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics [J Ocul Pharmacol Ther] 2024 Dec; Vol. 40 (10), pp. 675-679. Date of Electronic Publication: 2024 Nov 20. - Publication Year :
- 2024
-
Abstract
- Purpose: To evaluate the efficacy of subconjunctival tranexamic acid (TXA) in reducing intraoperative bleeding, shortening surgery duration, and improving postoperative outcomes in pterygium surgery. Methods: In this double-blind, randomized controlled trial, 50 eyes of 50 patients undergoing pterygium surgery were randomly assigned to receive either subconjunctival injection of 0.25 mL of 5% TXA (TXA group, n = 25) or an equivalent volume of saline (control group, n = 25). Baseline characteristics, including age, gender, working environment, allergies, preoperative logMAR best-corrected visual acuity, and systemic anticoagulant or antiplatelet therapy, were similar between the groups. The primary outcome measures were intraoperative bleeding, surgery duration, and the number of eye spears used. Secondary outcome measures included postoperative visual acuity and pterygium recurrence rates at 3 years post-surgery. Results: No significant differences were observed between the TXA group and the control group in terms of surgery duration (445.3 ± 94.8 s vs. 423.5 ± 80.6 s, P = 0.40), the number of eye spears used (3.5 ± 2.4 vs. 3.5 ± 2.6, P = 0.97), or the weight of absorbed blood (1.94 ± 1.40 grams vs. 1.90 ± 1.25 grams, P = 0.91). Additionally, there were no significant differences in postoperative visual acuity (0.14 ± 0.13 logMAR vs. 0.20 ± 0.19 logMAR, P = 0.39) or pterygium recurrence rates at 3 years post-surgery (8.0% vs. 4.4%, P = 0.60). Subconjunctival TXA injection was safe, with no reported adverse events or complications associated with its use. Conclusion: Subconjunctival injection of TXA did not significantly reduce intraoperative bleeding, shorten surgery duration, or improve postoperative outcomes in pterygium surgery. The intervention was safe and well-tolerated, but further research is warranted to explore alternative interventions or modifications to the surgical technique that may improve outcomes in pterygium surgery.
- Subjects :
- Humans
Double-Blind Method
Female
Male
Middle Aged
Visual Acuity drug effects
Blood Loss, Surgical prevention & control
Blood Loss, Surgical statistics & numerical data
Adult
Treatment Outcome
Aged
Conjunctiva
Combined Modality Therapy
Pterygium surgery
Pterygium drug therapy
Tranexamic Acid administration & dosage
Tranexamic Acid therapeutic use
Tranexamic Acid adverse effects
Mitomycin administration & dosage
Mitomycin therapeutic use
Sclera surgery
Antifibrinolytic Agents administration & dosage
Antifibrinolytic Agents therapeutic use
Antifibrinolytic Agents adverse effects
Subjects
Details
- Language :
- English
- ISSN :
- 1557-7732
- Volume :
- 40
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 39562525
- Full Text :
- https://doi.org/10.1089/jop.2024.0068